Wilken, O’Shea Talk Acquisition of HS Pharmaceuticals and What It Means for The Future Of XCRT

Wilken, O'Shea Talk Acquisition of HS Pharmaceuticals and What It Means for The Future Of XCRT

CEO Mike O’Shea of Xcelerate, Inc., a development stage startup focused on the development of cutting-edge medtech applications, met with SmallCapVoice.com to discuss the recent appointment of a new board member and the acquisition of a rather sizeable patent portfolio.

Format

PNG

Source

Xcelerate Inc.

Downloads